ST. PAUL, Minn.--(BUSINESS WIRE)--EnteroMedics Inc. (NASDAQ: ETRM) announced today that data from sub-group analyses of certain co-morbidities seen in patients during its feasibility studies, VBLOC-RF1 and VBLOC-RF2, were presented today at a general session of the 13th World Congress on Obesity Surgery of the International Federation for the Surgery of Obesity and metabolic disorders (IFSO), being held September 24-27 in Buenos Aires, Argentina. James Toouli, M.D., Professor of Surgery at Flinders University in Adelaide, Australia, presented the results, which included sub-analyses conducted to understand how EnteroMedics’ VBLOC™ vagal blocking therapy affects two co-morbidities frequently associated with obesity: type 2 diabetes and hypertension.
